Stay updated with breaking news from Rhythm Engine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Phase 3 clinical trial design reflects feedback obtained during recent discussions with FDA -- -- 89 percent patients achieved primary endpoint with a BMI decrease greater than 5 percent at 16... | November 2, 2022
-- Book developed in collaboration with the Bardet-Biedl Syndrome Foundation -- -- BBS Global Day on Sept. 24 coordinated by BBS International -- ...
-- CARE-BBS multi-country survey of 242 caregivers of individuals with Bardet-Biedl syndrome (BBS) provides extensive details on impact of hyperphagia and...
-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second...
-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest Agreement